Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 19.8 USD 1.02% Market Closed
Market Cap: 398.6m USD

SLP's latest stock split occurred on Oct 2, 2007

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, SLP traded at 14.2 per share. Afterward, the share price was about 5.2249.

The adjusted shares began trading on Oct 2, 2007. This was SLP's 2nd stock split, following the previous one in Aug 14, 2006.

Last Splits:
Oct 2, 2007
2-for-1
Aug 14, 2006
2-for-1
Pre-Split Price
5.5369 14.2
Post-Split Price
5.2249
Before
After
Last Splits:
Oct 2, 2007
2-for-1
Aug 14, 2006
2-for-1

Simulations Plus Inc
Stock Splits History

SLP Stock Splits Timeline
Oct 2, 2007
Oct 2, 2007
Split 2-for-1
x2
Pre-Split Price
5.5369 14.2
Post-Split Price
5.2249
Before
After
Aug 14, 2006
Aug 14, 2006
Split 2-for-1
x2
Pre-Split Price
1.1405 5.85
Post-Split Price
1.0216
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.22 45.22 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
62.79 62.79 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Simulations Plus Inc
Glance View

Market Cap
398.7m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
14.35 USD
Overvaluation 28%
Intrinsic Value
Price
Back to Top